Table 2.
RMST of blood pressure treatment strategy, stratified by glycaemic treatment strategy
| Population | 5-year RMST or RMTL (95% CI) | ||
| Standard | Intensive | Difference | |
| Total population | n=2371 | n=2362 | |
| RMST, days, mean (95% CI) | 1714 (1700 to 1728) | 1716 (1701 to 1730) | 1.3 (−18.1 to 20.7) |
| RMTL due to CVD events | 86 (74 to 99) | 81 (69 to 94) | −4.9 (−22.1 to 12.4) |
| RMTL due to non-CV death | 24 (18 to 31) | 28 (21 to 35) | 3.6 (−5.7 to 12.9) |
| Standard glycaemic treatment | n=1178 | n=1184 | |
| RMST, days, mean (95% CI) | 1697 (1676 to 1719) | 1725 (1707 to 1744) | 28.1 (0.4 to 55.9) |
| RMTL due to CVD events | 103 (84 to 123) | 77 (61 to 94) | −26.0 (−51.0 to 0.9) |
| RMTL due to non-CV death | 24 (15 to 33) | 22 (13 to 31) | −2.2 (−14.5 to 10.2) |
| Intensive glycaemic treatment | n=1193 | n=1178 | |
| RMST, days, mean (95% CI) | 1731 (1713 to 1749) | 1706 (1685 to 1727) | −25.2 (−52.3 to 1.9) |
| RMTL due to CVD events | 70 (54 to 85) | 85 (67 to 104) | 15.8 (−7.9 to 39.5) |
| RMTL due to non-CV death | 25 (16 to 34) | 34 (24 to 44) | 9.4 (−4.4 to 23.2) |
The interaction between blood pressure treatment strategy and glycaemic treatment strategy on RMST was statistically significant (p=0.008).
CVD, cardiovascular disease; RMST, restricted mean survival time; RMTL, restricted mean time lost.